INTRAVENOUS IMMUNOGLOBULIN APPLICATION IN CLINICAL PRACTICE
https://doi.org/10.15690/pf.v10i1.586
Abstract
The article gives data on the structure and function of immunoglobulins. Given the multitude of mechanisms of their action, indications to their use are constantly expanding. At present, immunoglobulins are used as replacement and immunomodulatory therapy of multidirectional action (stimulation/suppression). Mechanisms of action and points of immunoglobulin intravenous application in clinical practice are covered on the basis of literary data. Advantages of the domestic drug for intravenous application are shown.
About the Authors
T. V. Latysheva
State Scientific Center «Immunology Institute» of the Federal Medical Biological Agency of Russia, Moscow, Russian Federation
Russian Federation
Russian Federation
E. A. Latysheva
State Scientific Center «Immunology Institute» of the Federal Medical Biological Agency of Russia, Moscow, Russian Federation
References
1. Baranov A.A., Tatochenko V.K., Bakradze M.D. Likhoradochnye sindromy u detei: rekomendatsii po diagnostike i lecheniyu. Pod obshch. red. A.A. Baranova, V.K. Tatochenko, M.D. Bakradze [Febrile Syndromes in Children: Recommendations for Diagnosis and Treatment. Edited by A.A. Baranov, V.K. Tatochenko, M.D. Bakradze]. Moscow, Soyuz pediatrov Rossii, 2011. 228 p.
2. Mussano E.D., Onetti L.B., Cadile I., Onetti C.M. Use of intravenous human immunoglobulin in rheumatic diseases. Rev. Fac. Cien. Med. Univ. Nac. Cordoba. 2012; 69(2): 90–6.
3. Bayry J., Negi V. S., Kaveri S. V. Intravenous immunoglobulin therapy in rheumatic diseases. Nat. Rev. Rheumatol. 2011 Jun; 7 (6): 349–59.
4. Eftimov F., Winer J. B., Vermeulen M., de Haan R., van Schaik I. N. Intra venous immunoglobulin for chronic inflammatory demyelinating poly radiculoneuropathy. Cochrane Database Syst. Rev. 2009 Jan 21; (1).
5. Durandy A., Kaveri S. V., Kuijpers T. W. et al. Intravenous immunoglobulins — understanding properties and mechanisms. Clin. Exp. Immunol. 2009; 158 (Suppl. 1): 2–13.
6. Fernandez-Cruz E., Kaveri S. V., Peter H. H., Durandy A., Cantoni N., Quinti I., Sorensen R., Bussel J. B., Danieli M. G., Winkel mann A., Bayry J., Kasermann F., Spath P., Helbert M. et al. 6th International. Immunoglobulin Symposium: poster presen tations. Clin. Exp. Immunol. 2009; 158 (Suppl. 1): 60–67.
7. Jolles S., Sewell W. A. C., Misbah S. A. Clinical uses of intravenous immunoglobulin. Clin. Exp. Immunol. 2005 Oct; 142 (1): 1–11.
8. Francisco A. Bonilla, Leonard Bernstein, David A. Khan, Zuhair K. Ballas et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Annals of Allergy, Asthma and Immunology. 2005, 94 (5): 1–60.
9. Bayry J., Lacroix-Desmazes S., Donkova-Petrini V., Carbonneil C., Misra N., Lepelletier Y., Delignat S., Varambally S., Oksen'hendler E., Levy Y., Debre M., Kazatchkine M. D., Hermine O., Kaveri S. V. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc. Natl. Acad. Sci USA. 2004; 101: 14210–14215.
10. Kaveri S. V., Maddur M. S., Hegde P., Lacroix-Desmazes S., Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin. Exp. Immunol. 2011 Jun; 164 (Suppl. 2): 2–5.
11. Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J. Clin. Immunol. 2008; 28 (Suppl. 10): 42–45.
12. Lacroix-Desmazes S., Kazatchkine M. D., Galicier L., Lepelletier Y., Webster D., Levy Y., Eibl M. M., Oksenhendler E., Hermine O., Kaveri S. V. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood. 2004; 104: 2441–2443.
13. Cunningham-Rundles C., Radigan L. Deficient IL-12 and dendritic cell function in common variable immune deficiency. Clin. Immunol. 2005 May; 115 (2): 147–153.
14. Mackay I. R., Leskovsek N. V., Rose N. R. The odd couple: a fresh look at autoimmunity and immunodeficiency. J Autoimmun. 2010; 35: 199–205.
15. Lucas M., Lee M., Lortan J., Lopez-Granados E., Misbah S., Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J. Allergy Clin. Immunol. 2010; Jun; 125 (6): 1354–1360.
16. Jordan S. Orange, William F. Grossman, Roberta J. Navickis, Mahlom M. Wilkes. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin. Immunol. 2010 Oct; 137 (1): 21–30.
17. Beloborodov V.B., Vitvitskaya I.M. Sovremennaya kontseptsiya primeneniya vnutrivennykh immunoglobulinov dlya vnutrivennogo vvedeniya pri sepsise i septicheskom shoke [The modern concept of the use of intravenous immunoglobulin for intravenous administration in sepsis and septic shock]. Available at: http://www.biotestpharma.ru/index.php?news=17
18. Calandra T., Baumgartner J. D. Anti-endotoxin therapy. Clinical trails for the treatment of sepsis (update in Intensive Care and emergency Medicine 19). Berlin Heideiberg: Springer. 1995. pp. 237–250.
19. Greenman P. L., Scheun R. M. N., Martin M. A., Wenzel R. P. et al. A controlled clinical trail of E5 murine mooclonal IgM antibody to endotoxin in the treatment of Gramnegative sepsis. J. Am. Med. Accoc.1991; 266: 1097–102.
20. Imbach P. 30 years of immunomodulation by intravenous immunoglobulin. Immunotherapy. 2012 Jul; 4 (7): 651–4.
21. Bayry J., Negi V., Kaveri S. V. Intravenous immunoglobulin therapy in rheumatic diseases. Nat. Rev. Rheumatol. 2011; 7 (6): 349–359.
22. Viard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., Hunziker T., Saurat J., Tschopp J., French L. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998; 282: 490–493.
23. Imbach P., Lazarus A., Kuhne T. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sang. 2010; 98: 385–394.
24. Samuelsson A., Towers T., Ravetch J. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001; 91: 484–486.
25. Le Pottier L., Sapir T., Bendaoud B., Youinou P., Shoenfeld Y., Pers J. O. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann. NY Acad. Sci. 2007; 1110: 426–432.
26. Ephrem A., Chamat S., Miquel C. et al. Expansion of D4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008; 111: 715–722.
27. Maddur M. S., Vani J., Hegde P., LacroixDesmazes S., Kaveri S. V.,Bayry J. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J. Allergy Clin. Immunol. 2011; 127 (3): 823–83.
28. Trautmann A., Akdis M., Schmid-Grendelmeier P., Bizzini F., Disch R., Brocker E. B., Blaser K., Akdis C. A. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J. Allergy Clin. Immunol. 2001; 108: 839–846.
Review
For citations:
Latysheva T.V., Latysheva E.A. INTRAVENOUS IMMUNOGLOBULIN APPLICATION IN CLINICAL PRACTICE. Pediatric pharmacology. 2013;10(1):26-30. (In Russ.) https://doi.org/10.15690/pf.v10i1.586
Views:
837
Email this article 